8-K: 89bio Reports Full Year 2023 Results, Advances NASH and SHTG Programs

89bio announced its full year 2023 financial results, highlighted positive clinical trial data for pegozafermin, and outlined plans to initiate Phase 3 trials for NASH.

Summary

• 89bio reported its financial results for the fourth quarter and full year ended December 31, 2023.
• The company plans to initiate Phase 3 trials for NASH in the first and second quarters of 2024.
• Long-term data from the Phase 2b ENLIVEN trial showed sustained benefits of pegozafermin at week 48.
• A follow-on offering in Q4 2023 raised $172.5 million in gross proceeds.
• As of December 31, 2023, the company had $578.9 million in cash, cash equivalents, and marketable securities.
• Research and development expenses for the year were $122.2 million, compared to $80.8 million in 2022.
• The company reported a net loss of $142.2 million for the year, compared to a net loss of $102.0 million in 2022.

Sentiment

Score: 7

Explanation: The sentiment is positive due to the strong cash position, advancement of clinical programs, and positive trial data, but tempered by the significant net loss and increased expenses.

Positives

• The company has a strong cash position of $578.9 million, providing financial stability for ongoing and planned trials.
• Positive long-term data from the Phase 2b ENLIVEN trial supports the potential of pegozafermin as a treatment for NASH.
• The company is advancing its Phase 3 trials for both NASH and SHTG.
• Successful end-of-Phase 2 meetings with the FDA and initial scientific advice from the EMA support the advancement of pegozafermin into Phase 3 for NASH.

Negatives

• The company experienced a significant net loss of $142.2 million for the year ended December 31, 2023.
• Research and development expenses increased substantially to $122.2 million for the year ended December 31, 2023.
• General and administrative expenses also increased to $29.0 million for the year ended December 31, 2023.

Risks

• The company's future success is heavily dependent on the success of its lead product candidate, pegozafermin.
• Clinical trial results may not be predictive of future outcomes.
• The company faces competition from other companies developing treatments for NASH and SHTG.
• The company's ability to raise additional capital is subject to market conditions and other factors.
• The company's financial results are unaudited and subject to change.

Future Outlook

The company plans to initiate Phase 3 trials for NASH in 2024 and expects topline results from the Phase 3 trial in SHTG in 2025. They are focused on advancing pegozafermin as a potential best-in-class treatment.

Management Comments

• In 2023, we advanced our late-stage clinical development programs and demonstrated the anti-fibrotic and metabolic benefits of pegozafermin, aligned our Phase 3 NASH program with regulatory agencies in the United States and Europe, initiated our Phase 3 trial for SHTG, and strengthened our financial position, said Rohan Palekar, Chief Executive Officer of 89bio.
• We are highly encouraged by the Phase 2b ENLIVEN data and the long-term efficacy and tolerability data, which demonstrated positive, sustained benefits over a 48-week period, which together, positions pegozafermin as a potential best-in-class FGF21.

Industry Context

This announcement is significant as it highlights the progress of 89bio in the competitive NASH and SHTG treatment landscape. The initiation of Phase 3 trials is a key milestone, and the positive long-term data from the ENLIVEN trial positions pegozafermin as a potential contender in the market.

Comparison to Industry Standards

• The $578.9 million cash position is strong compared to many other clinical-stage biopharmaceutical companies, providing a solid runway for development.
• The increase in R&D expenses is typical for a company advancing multiple programs into late-stage clinical trials.
• The net loss is substantial, but not uncommon for companies in this stage of development, as they invest heavily in research and clinical trials.
• Companies like Madrigal Pharmaceuticals (MDGL) and Viking Therapeutics (VKTX) are also developing NASH treatments, and 89bio's results will be closely watched in comparison to their progress.

Stakeholder Impact

• Shareholders will be impacted by the financial results and the progress of clinical trials.
• Employees will be impacted by the company's growth and expansion.
• Patients with NASH and SHTG may benefit from the development of pegozafermin.
• Creditors will be impacted by the company's financial performance.

Next Steps

• Initiate the Phase 3 ENLIGHTEN-Fibrosis trial in the first quarter of 2024.
• Initiate the Phase 3 ENLIGHTEN-Cirrhosis trial in the second quarter of 2024.
• Continue enrollment in the ENTRUST Phase 3 trial for SHTG.
• Report topline results from the ENTRUST Phase 3 trial in 2025.

Key Dates

Keywords

NASH, SHTG, pegozafermin, clinical trials, Phase 3, biopharmaceutical, liver disease, cardiometabolic, FGF21, ENLIVEN, ENLIGHTEN, ENTRUST